Brokerages expect Bio-Rad Laboratories, Inc. (NYSE:BIO) to report $610.65 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Bio-Rad Laboratories’ earnings. The lowest sales estimate is $599.00 million and the highest is $622.30 million. Bio-Rad Laboratories posted sales of $620.43 million in the same quarter last year, which indicates a negative year-over-year growth rate of 1.6%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Bio-Rad Laboratories will report full year sales of $2.88 billion for the current fiscal year, with estimates ranging from $2.27 billion to $4.06 billion. For the next financial year, analysts anticipate that the business will report sales of $2.50 billion, with estimates ranging from $2.33 billion to $2.82 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Bio-Rad Laboratories.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, November 1st. The medical research company reported $0.91 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.16 by ($0.25). The company had revenue of $545.10 million for the quarter, compared to analyst estimates of $541.23 million. Bio-Rad Laboratories had a net margin of 55.13% and a return on equity of 3.72%. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.91 earnings per share.

Several equities research analysts have issued reports on BIO shares. Morgan Stanley started coverage on shares of Bio-Rad Laboratories in a report on Thursday, September 20th. They issued an “equal weight” rating and a $335.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $420.00 price target on shares of Bio-Rad Laboratories in a report on Monday, September 24th. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Goldman Sachs Group started coverage on shares of Bio-Rad Laboratories in a report on Wednesday, October 17th. They issued a “buy” rating and a $350.00 price target on the stock. Finally, Barclays lowered their price target on shares of Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating on the stock in a report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $338.43.

Institutional investors have recently made changes to their positions in the business. Select Equity Group L.P. grew its holdings in shares of Bio-Rad Laboratories by 321.8% in the 3rd quarter. Select Equity Group L.P. now owns 186,923 shares of the medical research company’s stock worth $58,505,000 after purchasing an additional 142,604 shares during the last quarter. Bodenholm Capital AB bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth about $32,540,000. AQR Capital Management LLC grew its holdings in shares of Bio-Rad Laboratories by 163.4% in the 3rd quarter. AQR Capital Management LLC now owns 159,008 shares of the medical research company’s stock worth $49,768,000 after purchasing an additional 98,634 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Bio-Rad Laboratories by 1,258.0% in the 3rd quarter. First Trust Advisors LP now owns 102,437 shares of the medical research company’s stock worth $32,062,000 after purchasing an additional 94,894 shares during the last quarter. Finally, GW&K Investment Management LLC bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth about $20,890,000. 62.37% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories stock traded down $6.75 on Monday, hitting $256.23. The company’s stock had a trading volume of 263,148 shares, compared to its average volume of 191,080. The firm has a market capitalization of $7.88 billion, a PE ratio of 62.50, a price-to-earnings-growth ratio of 3.20 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.49 and a quick ratio of 3.16. Bio-Rad Laboratories has a one year low of $231.00 and a one year high of $345.15.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Bio-Rad Laboratories (BIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.